Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
暂无分享,去创建一个
J. Friedberg | B. Holkova | J. Goldschmidt | A. Forero-Torres | J. Sharman | R. Bordoni | R. Boccia | M. Palanca-Wessels | C. Yasenchak | Yinghui Wang | Robert Chen | G. Olsen | M. C. Palanca-Wessels
[1] R. Bouabdallah,et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly , 2015, British journal of haematology.
[2] R. Advani,et al. Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy , 2014 .
[3] H. Cohen,et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Scott E. Smith,et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy , 2014, Leukemia & lymphoma.
[5] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[6] Scott E. Smith,et al. Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma , 2013 .
[7] O. O’Connor,et al. CYP3A‐Mediated Drug–Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30‐Positive Hematologic Malignancies , 2013, Journal of clinical pharmacology.
[8] R. Advani,et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 , 2013, British journal of haematology.
[9] R. McNally,et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. , 2012, Blood.
[10] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Scher,et al. Under-representation of older adults in cancer registration trials: known problem, little progress. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Scott E. Smith,et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. , 2012, Blood.
[13] Martin Krapcho,et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .
[14] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Cohen,et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Wilkinson,et al. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. , 2009, Critical reviews in oncology/hematology.
[17] Benjamin D Smith,et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Horning,et al. Hodgkin lymphoma in older patients: an uncommon disease in need of study. , 2008, Oncology.
[19] H. Wildiers,et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Damon L. Meyer,et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates* , 2006, Journal of Biological Chemistry.
[22] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[23] H. Cohen,et al. Developing a cancer‐specific geriatric assessment , 2005, Cancer.
[24] H. Cohen,et al. Developing a cancer-specific geriatric assessment : A feasibility study , 2005 .
[25] L. Repetto,et al. Greater risks of chemotherapy toxicity in elderly patients with cancer. , 2003, The journal of supportive oncology.
[26] Damon L. Meyer,et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.
[27] B. Angus,et al. Hodgkin's disease in the elderly: a population‐based study , 2002, British journal of haematology.
[28] David Collett,et al. Statistical inference for binary data , 2002 .
[29] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[30] R Brookmeyer,et al. Reliability of the Blessed Telephone Information-Memory-Concentration Test , 1995, Journal of geriatric psychiatry and neurology.
[31] A. Stewart,et al. Physical Functioning Measures , 1992 .
[32] A. Stewart,et al. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach , 1992 .
[33] Diane Podsiadlo,et al. The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.
[34] C. Sherbourne,et al. The MOS social support survey. , 1991, Social science & medicine.
[35] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[36] C. Mettlin,et al. National survey of patterns of care for Hodgkin's disease , 1985, Cancer.
[37] G. Fillenbaum,et al. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. , 1981, Journal of gerontology.
[38] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[39] John McGrath,et al. Hodgkin’s Disease , 1933, JAMA.